Nevertheless, they noted almost perfect concordance in PD-L1 expression status between the BC foci (85%) and did not find differences in the prevalence of PD-L1 between luminal A, luminal B, HER2-enriched, and triple-negative BC subtypes in either site (51). The gene discussed is ERBB2; the disease is breast cancer.